HALOZYME THERAPEUTICS INC (HALO)

US40637H1095 - Common Stock

46.96  -0.36 (-0.76%)

After market: 46.96 0 (0%)

News Image
4 days ago - Chartmill

Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.

News Image
6 days ago - Chartmill

Looking for growth without the hefty price tag? Consider NASDAQ:HALO.

NASDAQ:HALO, a growth stock which is not overvalued.

News Image
9 days ago - Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.

For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.

News Image
25 days ago - Halozyme Therapeutics, Inc.

Halozyme to Present at Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present...

News Image
a month ago - Halozyme Therapeutics, Inc.

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire...

News Image
a month ago - Halozyme Therapeutics, Inc.

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec...

News Image
a month ago - Market News Video

Halozyme Therapeutics is Now Oversold (HALO)

News Image
a month ago - Halozyme Therapeutics, Inc.

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management...

News Image
2 months ago - Halozyme Therapeutics, Inc.

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted...

News Image
2 months ago - Halozyme Therapeutics, Inc.

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent...

News Image
2 months ago - Halozyme Therapeutics, Inc.

Halozyme to Report Third Quarter 2024 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results...

News Image
2 months ago - Market News Video

Halozyme Therapeutics is Now Oversold (HALO)

News Image
3 months ago - Halozyme Therapeutics, Inc.

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and...

News Image
3 months ago - USA News Group

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

News Image
3 months ago - USA News Group

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84%...